3SBio hits the big time with $6 billion cancer drug deal
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega…
FAST NEWS: Akeso raises $247 million through share placement
The Latest: Akeso Inc. (9926.HK) announced Sunday it has entered into placement agreements to issue 31.7 million shares to six investors priced at HK$61.28 per share, representing a 4.99% discount…
Innovent Bio hopes for plus-sized profits from obesity drug
The biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug Key Takeaways: Sales…
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
- Will Trump’s drug order put the brakes on China’s overseas pharma drive?
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
